Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q2 2025 · 10-Q
Revenue$102.69M$102.69M+45.6% vs Q2 2024 Net Income$10.81M$10.81MN/M vs Q2 2024 EPS Diluted$0.36$0.36N/M vs Q2 2024 Gross Profit$70,902,000+65.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived$10,420,000N/M Free Cash Flowderived$8,051,000N/M Margins · derivedGross margin69.0%+8.1 pt vs Q2 2024
Operating margin8.7%+23.7 pt vs Q2 2024
Net margin10.5%+51.9 pt vs Q2 2024
ended Jun 30, 2025 · filed Jul 29, 2025 · 29 d after period end